Trends in the use of mammography for early breast cancer detection in Switzerland: Swiss Health Surveys 2007 and 2012. by Fenner, Lukas et al.
Original article | Published 14 May 2018 | doi:10.4414/smw.2018.14603
Cite this as: Swiss Med Wkly. 2018;148:w14603
Trends in the use of mammography for early
breast cancer detection in Switzerland: Swiss
Health Surveys 2007 and 2012
Fenner Lukasab, Kässner Anjaa, Berlin Claudiaa, Egger Matthiasa, Zwahlen Marcela
a Institute of Social and Preventive Medicine, University of Bern, Switzerland
b Gesundheitsamt, Kanton Solothurn, Switzerland
Summary
AIMS: Breast cancer is the most common cancer in
women worldwide. We assessed changes in the use of
breast cancer screening 2007–2012 in Switzerland, and
associations with socioeconomic and health-related deter-
minants.
METHODS: We used the nationwide and representative
data from the Swiss Health Surveys 2007 and 2012. We
analysed the self-reported use of mammography in the
last 12 months (proportion of population) among women
aged 40–79 years, and opportunistic (without clinical
symptoms, initiated by the woman or a physician) and pro-
grammatic screening mammography (as part of a system-
atic screening programme). We performed multivariate lo-
gistic regression analyses (presented as adjusted odds
ratios, aORs).
RESULTS: The use of any mammography in the last 12
months declined from 19.1% (95% confidence interval [CI]
17.7–20.5%) in 2007 to 11.7% (95% CI 10.7–12.6%) in
2012. This decline was more pronounced in regions with a
long-standing or no cantonal breast cancer screening pro-
gramme (aOR 0.5, 95% CI 0.4–0.6, and aOR 0.5, 95%
CI 0.4–0.6, respectively), but remained relatively stable in
regions with a recently introduced programme (aOR 0.9,
95% CI 0.6–1.3, p-value from test for interaction 0.01).
Opportunistic screening dropped from 12.0% (95% CI
10.9–13.2%) in 2007 to 6.2% (95% CI 5.5–6.9%; p
<0.001) in 2012, whereas the use of programmatic mam-
mography remained stable at 3.1% (95% CI 2.6–3.7%).
Use of any mammography was higher in women aged
50–69 years, residing in a region with a systematic screen-
ing programme in place, and women having a private hos-
pital stay insurance, but was not associated with educa-
tion level and non-Swiss citizenship.
CONCLUSIONS: Overall attendance of breast cancer
screening is low in Switzerland and decreased between
2007 and 2012, despite expanding cantonal mammogra-
phy screening programmes. Many factors may have con-
tributed to this decline, including the ongoing scientific and
public debates on the value of breast cancer screening.
Key words: self-reported, breast cancer, screening, pre-
vention, screening programme, Switzerland
Introduction
Breast cancer in women is among the malignancies with
the highest incidence and mortality in high-income coun-
tries such Switzerland [1]. More than 5700 women are af-
fected in Switzerland each year, and 1400 die from breast
cancer each year [1]. It is therefore a major public health
problem. European and international associations recom-
mend mammography screening of women aged 50 to 70
years for early detection of breast cancer [2]. Screening
aims at detecting cancer or its precursor lesions early, when
they are in a curable state. However, the value of screening
programmes is a matter of debate because of the limited ef-
fect on mortality, false-positive findings requiring diagnos-
tic workup and possible overdiagnosis and overtreatment
[3–7]. In Switzerland, screening attendance is higher in the
French-speaking area (mainly screening programmes) than
in the German-speaking (mainly opportunistic screening)
[8, 9], and this difference does not appear to be explained
by sociodemographic or health-related factors [9]. Uptake
of breast cancer screening has also been reported to be in-
creased in women with higher incomes [10].
In 1995, the Swiss Federal Office of Public Health and
the Swiss Cancer League adopted a national strategy for
prevention, screening and care for breast cancer. Although
a national screening programme has repeatedly been sug-
gested in subsequent national strategy reports, a national
programme has not been established [11], and Swiss can-
tons may or may not put a programme in place. Swiss com-
pulsory basic health insurance reimburses mammography
screening without access payments for women aged 50 to
70 years (at average risk), if carried out within a cantonal
screening programme with systematic invitation of women
and quality control of the screening process. Breast cancer
screening attendance was expected to change after canton-
al mammography programmes were expanded over time.
Up to 2012, 9 out of 26 cantons introduced mammography
screening, 5 after 2005 [1].
We aimed to study time trends and associations of sociode-
mographic characteristics and health-related factors with
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the changes of breast cancer screening in Switzerland be-
tween 2007 and 2012, using data from the nationwide rep-
resentative health surveys.
Methods
Survey sample
The Swiss Health Interview Survey (SHIS) is a cross-sec-
tional survey conducted every five years since 1992 by the
Swiss Federal Statistical Office (SFSO). A random mul-
tistage probability sample is drawn from all residents in
Switzerland, as previously reported [8, 12, 13]. The health
survey collects data through computer-assisted telephone
interviews (oral) and self-administered questionnaires
(written). The interviews are conducted in the three official
languages (German, French and Italian). In this study, we
analysed the two most recent available data sets (from
2007 and 2012). We included 11,292 female respondents
aged 40 to 79 years who responded to a written question-
naire, 5123 in 2007 and 6169 in 2012.
Data collection
The main questions on breast cancer detection were:
– Have you already had mammography? (yes, no, un-
known);
– When was the mammography done last time? (date, if
unknown: last 12 months, yes/no);
– Who initiated the last mammography? (initiated by the
woman or a physician, invitation by a mammography
screening program, unknown); and
– What was the reason for the last mammography? (pre-
ventive examination/check-up without clinical symp-
toms, diagnostic workup, follow-up evaluation, un-
known).
Additional data collected included sociodemographic, so-
cioeconomic and health-related information, citizenship,
screening for colon cancer (Haemoccult, endoscopy), and
type of hospital stay insurance (basic, semiprivate, private,
other). Regional availability of breast cancer screening
programmes during the study period was defined as fol-
lows: cantons with long-standing programmes established
before 2005, cantons who introduced a programme after
2005 and cantons without a programme [14].
Statistical analysis
For each survey year 2007 and 2012, we calculated the
proportions of the female population reporting having
mammography in the last 12 months, the proportion of
mammography as part of a screening programme (pro-
grammatic mammography) and the proportion of screen-
ing mammography initiated by the woman or a physician
(opportunistic mammography). We used univariate and
multivariate logistic regression models to calculate unad-
justed and adjusted odds ratios (aORs), with the following
outcome variables: mammography in the last 12 months
versus not done, programmatic versus non-programmatic
mammography (last mammography), and opportunistic vs.
all other mammography (last mammography). An interac-
tion term with the year of survey and the variable of inter-
est was also included. In all analyses, we used the survey
weights provided by the SFSO, and reported all propor-
tions and ORs with the corresponding 95% confidence in-
tervals (95% CI). All analyses were performed in Stata ver-
sion 15.1 (College Station, Texas, USA).
The geographical distribution of the population reporting
on mammography examinations were visualized at the
cantonal level (see supplementary fig. S1 in appendix 1)
using ArcGIS version 10.5 (Redlands, CA, USA).
Ethics statement
Data were de-identified before analysis. We obtained per-
mission to analyse and publish the data through a contract
with the SFSO (Ref. 624.110-1).
Results
Self-reported mammography in different population
groups and trends over time
The frequency of women reporting any mammography
in the past 12 months decreased from 19.1% (95% CI
17.7–20.5%) in 2007 to 11.6 (10.7–12.7%) in 2012 (table
1, p <0.001). The decline in self-reported mammography
was more pronounced in regions with either a long-stand-
ing or no cantonal screening programme (aOR 0.5, 95%
CI 0.4–0.6, and 0.5, 95% CI 0.4-0.6; supplementary table
S1 in appendix 1), but remained relatively stable in regions
with a recently introduced screening programme (aOR 0.9,
95% CI 0.6–1.3, p-value from test for interaction 0.01).
The decline was not associated with age, regions, urban/
rural setting, citizenship, education level, and hospital stay
insurance (p >0.05; table S1). When the analysis was re-
stricted to the age group of 50 to 69 years for whom
breast cancer screening is recommended [14], the propor-
tion of self-reported screening mammography (opportunis-
tic and programmatic) was 21.2% (19.3–23.3%) in 2007
and 13.3% (12.0–14.8%) in 2012 (overall: 17.1%, 95% CI
15.9–18.3%).
Both in 2007 and 2012, the proportion of women with any
self-reported mammography was higher in the age group
of 50 to 70 years, in women with secondary/tertiary edu-
cation, past smokers, women with a bad / very bad self-
reported health status, women who also had a screening
for colorectal cancer (Haemoccult and endoscopy), and
women with private/semiprivate hospital stay insurance
(table 1). We also observed regional differences: the
French-speaking area and the southern part of Switzerland
had a higher rate of self-reported mammography, as did re-
gions with a long-standing cantonal screening programme.
A lower rate of self-reported mammography was observed
in the German-speaking area of Switzerland and in regions
with no or recently introduced screening programmes. The
regional differences in the use of any mammography in the
last 12 months are shown in figure 1, and the use of oppor-
tunistic and programmatic mammography in supplemen-
tary figure S2.
Use of opportunistic and programmatic screening
mammography in different population groups and
trends over time
Opportunistic screening mammography in the last 12
months dropped from 12.0% (95% CI 10.9–13.2%) in
2007 to 6.2% (95% CI 5.5–6.9%; p<0.001) in 2012, where-
as the use of programmatic screening mammography re-
mained stable (3.1 and 3.1%, p = 0.99; table 1). The use of
mammography for other reasons (diagnostic workup, fol-
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low-up) decreased slightly, from 4.0% (95% CI 3.3–4.7%)
in 2007 to 2.4% (95% CI 1.9–2.9%; p <0.001). Oppor-
tunistic and programmatic mammography were mainly
performed in the age group 50 to 70 years, and in regions
with a long-standing breast cancer screening programme in
place.
The decline in opportunistic screening was similar in re-
gions with or without a screening programme, but pro-
grammatic screening declined in regions with a long-stand-
ing programme (aOR 0.6, 95% CI 2.4–8.4) and increased
in regions with a recently introduced programme (aOR 4.5,
95% CI 2.6–15.7; supplementary table S1 in appendix 1).
The decline in opportunistic and programmatic mammog-
raphy was not associated with patient or health system-rel-
evant factors (p-value from test for interaction >0.1).
Table 1: Percent of women (with 95% confidence intervals) aged 40 to 79 years reporting having undergone different types of mammography in the last 12 months in Switzer-
land, 2007 and 2012.
2007 2012Characteristic
Any mammography Opportunistic mam-
mography
Programmatic mam-
mography
Any mammography Opportunistic
mammography
Programmatic mammog-
raphy
Total 19.05 (17.68–20.49) 12.00 (10.85–13.24) 3.10 (2.56–3.75) 11.61 (10.65–12.64) 6.15 (5.46–6.92) 3.10 (2.62–3.65)
Age group, years
40–49 10.97 (8.95–13.37) 7.50 (5.74–9.74) 0.38 (0.13–1.06) 7.22 (5.84–8.88) 4.23 (3.20–5.56) 0.57 (0.32–1.02)
50–59 24.67 (21.81–27.78) 15.00 (12.66–17.69) 5.65 (4.29–7.42) 16.44 (14.26–18.88) 7.53 (6.10–9.27) 5.77 (4.54–7.31)
60–69 27.61 (24.63–30.80) 17.02 (14.57–19.79) 5.70 (4.25–7.62) 15.82 (13.73–18.17) 8.74 (7.24–10.53) 5.22 (3.96–6.87)
70–79 14.84 (12.09–18.08) 9.50 (7.32–12.24) 1.04 (0.55–1.99) 7.77 (6.08–9.87) 4.60 (3.31–6.35) 1.41 (0.81–2.43)
BMI group
Underweight 17.43 (12.18–24.31) 11.78 (7.37–18.30) 3.81 (1.90–7.48) 13.23 (8.39–20.25) 7.38 (4.15–12.79) 4.31 (1.55–11.41)
Normal 18.44 (16.70–20.32) 12.02 (10.52–13.70) 2.65 (2.10–3.35) 10.66 (9.54–11.91) 5.93 (5.07–6.92) 2.72 (2.19–3.39)
Overweight 20.88 (18.12–23.95) 12.51 (10.31–15.10) 3.57 (2.37–5.35) 12.73 (10.78–14.98) 6.55 (5.18–8.25) 3.56 (2.66–4.74)
Obese 18.97 (14.83–23.94) 10.15 (7.41–13.76) 4.62 (2.55–8.21) 13.13 (9.99–17.06) 5.85 (4.12–8.23) 3.39 (1.95–5.83)
Cantonal mammography screening programme*
None 16.67 (15.02–18.46) 11.87 (10.46–13.45) 0.58 (0.25–1.31) 8.67 (7.61–9.87) 5.56 (4.75–6.51) 0.46 (0.27–0.77)
Recently introduced 14.08 (11.31–17.39) 10.00 (7.58–13.07) 1.59 (0.96–2.63) 12.90 (10.37–15.94) 5.13 (3.58–7.31) 6.63 (4.81–9.06)
Long-standing 29.75 (26.39–33.35) 13.67 (11.13–16.68) 12.05 (9.92–14.56) 18.86 (16.54–21.43) 8.38 (6.82–10.25) 8.18 (6.65–10.02)
Setting
Urban 20.13 (18.47–21.90) 12.90 (11.51–14.44) 3.14 (2.48–3.96) 11.94 (10.80–13.19) 6.54 (5.70–7.49) 2.75 (2.24–3.36)
Rural 15.89 (13.72–18.34) 9.37 (7.62–11.46) 3.00 (2.23–4.03) 10.69 (9.05–12.58) 5.09 (4.04–6.40) 4.06 (3.02–5.43)
Citizenship
Swiss 18.82 (17.51–20.21) 11.94 (10.83–13.15) 2.90 (2.47–3.41) 11.27 (10.34–12.28) 5.97 (5.29–6.74) 3.25 (2.75–3.84)
Non–Swiss 20.44 (15.43–26.56) 12.37 (8.43–17.78) 4.29 (2.12–8.48) 13.18 (10.18–16.90) 6.98 (4.96–9.75) 2.39 (1.30–4.34)
Education level
Primary 19.34 (15.95–23.25) 11.02 (8.55–14.09) 4.55 (2.71–7.53) 12.81 (10.23–15.92) 6.37 (4.71–8.56) 3.55 (2.41–5.20)
Profession 18.28 (16.61–20.07) 11.63 (10.22–13.22) 2.76 (2.20–3.45) 11.29 (10.09–12.61) 6.65 (5.72–7.73) 2.66 (2.11–3.36)
Secondary 25.05 (17.52–34–47) 16.02 (9.68–25.34) 4.94 (2.54–9.41) 13.91 (10.46–18.27) 6.04 (3.94–9.13) 5.08 (3.01–8.43)
Tertiary 20.12 (16.93–23.74) 13.21 (10.55–16.42) 2.64 (1.69–4.11) 10.53 (8.63–12.78) 4.92 (3.66–6.59) 2.95 (2.07–4.17)
Smoking
Never smoked 19.33 (17.42–21.40) 12.25 (10.67–14.03) 3.32 (2.50–4.40) 10.33 (9.13–11.66) 5.51 (4.66–6.52) 2.80 (2.21–3.53)
Past smoker 20.86 (18.17–23.83) 12.17 (10.01–14.72) 3.71 (2.82–4.88) 14.72 (12.50–17.26) 7.46 (5.98–9.28) 3.66 (2.62–5.11)
Current smoker 16.16 (13.64–19.05) 11.10 (8.91–13.75) 1.79 (1.20–2.67) 11.53 (9.62–13.75) 6.36 (4.93–8.18) 3.24 (2.31–4.53)
Self–reported health status
Very good 18.14 (15.17–21.54) 12.78 (10.22–15.86) 2.50 (1.72–3.61) 11.01 (9.46–12.78) 6.80 (5.59–8.25) 2.61 (1.88–3.62)
Good 18.47 (16.81–20.24) 11.86 (10.46–13.42) 3.11 (2.48–3.89) 10.26 (9.04–11.64) 5.57 (4.64–6.67) 2.72 (2.17–3.40)
Moderate 20.00 (16.28–24.33) 10.43 (7.86–13.72) 4.05 (2.18–7.43) 14.59 (11.87–17.80) 6.12 (4.58–8.14) 4.67 (3.18–6.80)
Bad 24.93 (17.11–34.82) 13.53 (7.55–23.07) 1.73 (0.56–5.25) 18.60 (12.78–26.26) 9.27 (5.14–16.15) 5.10 (2.48–10.18)
Very bad 61.76 (36.00–82.26) 32.64 (10.32–67.10) 8.54 (1.98–30.14) 23.55 (7.85–52.71) 0 2.73 (0.65–10.80)
Haemoccult screening†
Yes 20.60 (18.05–23.41) 14.33 (12.07–16.94) 2.67 (1.93–3.69) 13.75 (11.75–16.04) 7.25 (5.89–8.90) 3.53 (2.53–4.91)
No 18.34 (16.74–20.07) 10.96 (9.67–12.40) 3.27 (2.59–4.13) 10.92 (9.83–12.11) 5.79 (5.00–6.69) 2.97 (2.44–3.60)
Endoscopy screening†
Yes 24.42 (21.55–27.53) 15.44 (13.04–18.18) 3.73 (2.76–5.03) 14.94 (13.07–17.03) 8.05 (6.71–9.64) 3.63 (2.70–4.87)
No 17.42 (15.88–19.08) 10.95 (9.67–12.38) 2.92 (2.29–3.70) 9.95 (8.88–11.13) 5.20 (4.44–6.08) 2.84 (2.33–3.46)
Hospital stay insurance
Basic 16.78 (15.05–18.66) 9.79 (8.40–11.38) 3.35 (2.59–4.33) 10.84 (9.66–12.14) 5.29 (4.50–6.22) 3.28 (2.66–4.04)
Semiprivate 20.25 (17.67–23.10) 13.84 (11.63–16.39) 2.20 (1.45–3.32) 14.10 (12.02–16.46) 8.25 (6.64–10.20) 2.74 (2.00–3.75)
Private 26.36 (22.30–30.86) 17.44 (14.08–21.40) 3.99 (2.65–5.96) 11.63 (8.98–14.93) 7.09 (5.18–9.63) 2.90 (1.56–5.32)
Other 22.06 (10.04–41.78) 11.84 (4.13–29.50) 2.56 (0.62–9.97) 6.47 (3.18–12.71) 4.07 (1.72–9.34) 1.11 (0.28–4.40)
BMI = body mass index; OR = odds ratio Any mammography: mammography in the last 12 months; opportunistic mammography: screening mammography without clinical symp-
toms; programmatic mammography: mammography initiated by a systematic cancer screening programme. The category “mammography for other reasons” (diagnostic workup,
follow-up) is not shown. * Recently introduced programmes: Neuchatel, Jura, Thurgau, St. Gallen, Graubünden; long-standing programmes: Fribourg, Waadt, Wallis, Genf † Ever
in life
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The proportion of opportunistic screening mammography
among all self-reported mammography decreased between
2007 and 2012 (from 63.0 to 53.0%), whereas the propor-
tion of programmatic mammography increased (from 16.3
to 26.7%); the proportion of mammography for other rea-
sons remained stable (20.7 and 20.3% in 2007 and 2012,
respectively).
Figure 1: Geographical distribution of self-reported mammography in the last 12 months (percentage of population) in women aged 40-79
years in Switzerland, 2007 and 2012.
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Individual and health system factors associated with
the use of mammography
As shown in table 2, having undergone any mammography
in the last 12 months was associated with the age group 50
to 69 years, very bad self-reported health status, having un-
dergone colorectal cancer screening with endoscopy, pri-
vate and semiprivate hospital stay insurance. Use of mam-
mography was also less likely in 2012 (aOR 0.5, 95% CI
0.5–0.6) than in 2007. There was no association with non-
Swiss citizenship or educational level (table 2).
Supplementary table S2 (appendix 1) shows the factors as-
sociated with the use of programmatic mammography. The
use of programmatic mammography was more likely in
regions with a recently introduced screening programme
(aOR 9.3, 95% CI 5.1–17.1), and regions with a long-
standing programme (aOR 24.1, 95% CI 13.4–43.5) than
Table 2: Associations of having undergone mammography in the last 12 months with sociodemographic characteristics and health-related factors (as compared with no mam-
mography performed) in women aged 40 to 79 years in Switzerland, 2007 and 2012.
Mammography vs no mammography in the last 12 monthsCharacteristic
Unadjusted OR
(95% CI)
p-value Adjusted OR
(95% CI)
p-value
Year of survey
2007 1 1
2012 0.56 (0.49–0.64)
<0.001
0.52 (0.45–0.60)
<0.001
Age group, years
40–49 0.39 (0.32–0.47) 0.42 (0.35–0.52)
50–59 1 1
60–69 1.07 (0.91–1.25) 0.99 (0.83–1.17)
70–79 0.48 (0.39–0.59)
<0.001
0.44 (0.35–0.55)
<0.001
BMI group
Underweight 1.06 (0.76–1.49) 1.08 (0.76–1.55)
Normal 1 1
Overweight 1.17 (1.00–1.37) 1.17 (0.99–1.38)
Obese 1.09 (0.87–1.38)
0.25
1.11 (0.87–1.41)
0.16
Cantonal mammography screening programme*
None 1 1
Recently introduced 1.09 (0.89–1.33) 1.21 (0.98–1.49)
Long-standing 2.17 (1.88–2.52)
<0.001
2.27 (1.93–2.66)
<0.001
Setting
Urban 1 1
Rural 0.80 (0.69–0.93)
0.003
0.87 (074–1.02)
0.080
Citizenship
Swiss 1 1
Non-Swiss 1.11 (0.88–1.40)
0.39
1.12 (0.86–1.45)
0.39
Education level
Primary 1 1
Profession 0.93 (0.77–1.13) 1.00 (0.82–1.24)
Secondary 0.93 (0.77–1.13) 1.13 (0.81–1.58)
Tertiary 0.92 (0.73–1.16)
0.68
0.96 (0.75–1.24)
0.79
Smoking
Never smoked 1 1
Past smoker 1.25 (1.07–1.47) 1.11 (0.94–1.31)
Current smoker 0.92 (0.78–1.09)
0.003
0.93 (0.75–1.08)
0.12
Self-reported health status
Very good 1 1
Good 1.14 (0.98–1.34) 0.96 (0.81–1.15)
Moderate 1.32 (1.06–1.64) 1.16 (0.91–1.47)
Bad 1.82 (1.28–2.59) 1.49 (1.02–2.18)
Very bad 4.13 (1.83–9.30)
<0.001
2.93 (1.28–6.71)
0.008
Haemoccult screening†
Yes 1.25 (1.07–1.44) 1.08 (0.92–1.27)
No 1
0.003
1
0.34
Endoscopy screening†
Yes 1.44 (1.25–1.65) 1.36 (1.17–1.59)
No 1
<0.001
1
<0.001
Hospital stay insurance
Basic 1 1
Semiprivate 1.34 (1.15–1.56) 1.25 (1.06–1.47)
Private 1.53 (1.26–1.86) 1.36 (1.10–1.67)
Other 0.84 (0.45–1.56)
<0.001
0.99 (0.53–1.87)
0.007
95% CI = 95% confidence interval; BMI = body mass index; OR = odds ratio Model adjusted for all variables included in the table. * Recently introduced programmes: Neuchatel,
Jura, Thurgau, St. Gallen, Graubünden; long-standing programmes: Fribourg, Waadt, Wallis, Genf † Screening for colon cancer ever in life
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in other regions. Programmatic mammography was more
likely in the age groups 50-69 years, and in women with
a basic hospital stay insurance. Year of survey, citizenship,
educational level, and having undergone a colorectal can-
cer screening were all not associated with programmatic
mammography (table S2). A similar pattern was observed
for the use of opportunistic mammography (table S3).
Discussion
We analysed data from two representative, nationwide
health surveys in Switzerland. We found that the self-re-
ported use of mammography among women aged 40 to 79
years in Switzerland declined from 19% in 2007 to 12% in
2012. The use of opportunistic mammography in the last
12 months dropped from 12.0 to 6.2%, whereas the use of
programmatic screening mammography remained stable at
3.1%. Proportionally, the use of programmatic screening
increased. There were also regional differences in the use
of mammography.
In Switzerland and other countries, mammography screen-
ing is recommended for women aged between 50 and 69
years every 2 years [2]. The reported use of mammography
in the last 12 months by approximately 20% of women
aged 50 to 69 years would correspond to around 40% in
the recommended time interval of 2 years. This is rela-
tively low compared with other European countries, where
screening rates range from 23% in the Slovak Republic
to over 80% in Portugal, Denmark, Finland and Slovenia
in 2014 [15]. The European Guidelines suggest a target
screening rate of >75% among eligible women aged 50 to
70 years [2]. We also found that overall the use of mam-
mography declined from 19% in 2007 to 12% in 2012.
This decline might reflect the ongoing debate about the
benefits (mortality) and harms (false-positive results re-
quiring diagnostic workup, overdiagnosis, overtreatment)
of breast cancer screening [3, 5–7, 16], and the increasing
emphasis that is put on ensuring informed decision making
[4]. It has been shown that the level of information of the
public appears to strongly influence willingness to partici-
pate in screening programmes [17]. Indeed, the positive ef-
fects of breast cancer screening were initially overestimat-
ed by women in Switzerland and elsewhere [18], but this
may have changed over time to a more critical public view
on breast cancer screening.
In absolute numbers, opportunistic screening mammogra-
phy in the last 12 months halved between 2007 and 2012
(12 to 6%), while programmatic screening remained sta-
ble at a low level (3%) overall, but tended to decrease
in regions with a long-standing programme and increase
in regions with a recently introduced programme. Propor-
tionally, programmatic screening mammography increased
during the study period, while opportunistic screening de-
creased. These findings suggest at least a temporarily pos-
itive effect of the established cantonal screening pro-
grammes, particularly in more recently introduced pro-
grammes, but also suggests a shift from individual screen-
ing to cantonal programmes. Screening programmes as a
public health measure have been established in Switzer-
land since 1999, starting in the cantons of Geneva, Lau-
sanne and Valais [14]. These screening programmes were
initiated on the basis of evidence from the literature, but
also evaluations of systematic screening programmes in
countries such as Sweden and The Netherlands [19, 20].
Potential advantages of systematic programmes over indi-
vidualised opportunistic screening include better informa-
tion of women about the possible benefits and harms of
screening, quality control of mammography and monitor-
ing of the diagnostic workup of suspicious mammography
findings [6]. Another important advantage is that organised
screening programmes in principle ensure equal access for
all women. In our study, lower education level was not as-
sociated with lower participation in breast cancer screen-
ing, in contrast to a previous study using the SHIS data of
2002 [10]. This could suggest that inequities in access may
have levelled off. On the other hand, women attending oth-
er cancer screening programmes and women with a private
hospital stay insurance, had a higher uptake of mammog-
raphy, possibly reflecting individuals with a higher health
awareness [10].
In Switzerland, uptake of breast cancer screening was
higher in regions with long-standing screening pro-
grammes, lower in regions where screening programmes
have been recently introduced, and lowest in regions where
no programme exists. Eleven cantonal screening pro-
grammes had been established up to 2012, the time of the
latest survey, and these programmes covered 37% of the
eligible population [14]. The regions with long-standing
screening programmes correspond to the French-speaking
area of the country, where a high uptake has previously
been demonstrated [8, 9], whereas opportunistic screening
dominates in the German-speaking area. This difference
did not seem to be influenced by sociodemographic or
health-related factors [9], but appears to be driven by pub-
lic promotion of screening, recommendations by health-
care providers, and cultural factors, including different be-
liefs and attitudes. Interestingly, the decrease in the use
of mammography observed in our study was more pro-
nounced in regions with a generally higher uptake. Despite
the drop in self-reported mammography screening, breast
cancer mortality in Switzerland continues to decrease,
probably because of improvements in treatment, as well as
changes in cause-of-death coding [1, 6].
Our study is limited by the fact that self-reported mam-
mography may not reflect the number of screened women,
and the distinction between opportunistic, programmatic
and diagnostic mammography might not always be ac-
curate. However, a study from Israel showed reasonable
agreement between self-reported and registered mammog-
raphy [21], and a study of post-treatment mammography
surveillance showed a high congruence, particularly for re-
sults in the past 7 to 12 months [22]. Moreover, a valida-
tion study from colon cancer screening also showed a good
agreement between self-reporting and patient charts [23].
Finally, the SHIS is a nationwide, representative survey,
and analyses were weighted and adjusted for a wide range
of important sociodemographic and health-related factors.
In conclusion, uptake of breast cancer screening is low
in Swiss women and decreased between 2007 and 2012.
Many factors may have contributed to this decline. The on-
going debates on the usefulness of screening programmes
in Switzerland [4, 7, 24, 25] and the limited evidence for
breast cancer mortality reduction by screening [6], espe-
cially when uptake of mammography is low, are likely to
have influenced the trend in mammography attendance and
the public willingness to accept screening tests in Switzer-
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land. The next survey round of 2017 (data available end
of 2018) might show further trends. Future surveys should
include additional questions to better distinguish between
diagnostic, opportunistic, and programmatic mammogra-
phy, as well as questions on the willingness to participate
in screening programs. Our findings should be taken into
consideration for future adaption of public information and
implementation of cancer screening programs such as sys-
tematic screening for colorectal cancers with substantial
and long-lasting benefits [26–28].
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Appendix 1 Supplementary data
Table S1: Factors associated with the temporal change in self-reported mammography in the last 12 months in women (age 40 to 79 years) in Switzerland, 2007 and 2012.
Any mammography Opportunistic screening Programmatic screeningCharacteristic
(groups) Adjusted OR
(95% CI)
p-value* Adjusted OR
(95% CI)
p-value* Adjusted OR
(95% CI)
p-value*
Age (four age groups) – 0.32 – 0.93 – 0.69
Setting (urban/rural) – 0.36 – 0.60 – 0.14
Citizenship (Swiss/non-Swiss) – 0.51 – 0.46 – 0.22
Education level (primary to tertiary) – 0.48 – 0.16 – 0.95
Hospital stay insurance (general, semipri-
vate/private)
– 0.055 – 0.34 – 0.80
Cantonal mammography screening pro-
gramme†
0.012 0.38 <0.001
None 0.47 (0.39–0.57) – 0.91 (0.30–2.76)
Recently introduced 0.87 (0.61–1.26) – 4.50 (2.41–8.41
Long-standing 0.50 (0.39–0.64) – 0.57 (0.42–0.79)
CI = confidence interval; OR = odds ratio * p-values from interaction tests † Recently introduced programmes: Neuchatel, Jura, Thurgau, St. Gallen, Graubünden; long-standing
programmes: Fribourg, Waadt, Wallis, Genf Estimates derived from regression models adjusted for year of survey, age, body mass index group, setting, citizenship, education
level, smoking, self-reported health status, Haemoccult/endoscopy screening, hospital stay insurance, and participation in cantonal screening program for breast cancer. An in-
teraction with the year of survey and the variable of interest was included.
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Table S2: Associations of programmatic mammography (within a systematic screening programme) with sociodemographic characteristics and health-related factors compared
with all other women aged 40–79 years in Switzerland, 2007 and 2012.
Women reporting programmatic mammography compared with all othersCharacteristic
Unadjusted OR
(95% CI)
p–value Adjusted OR
(95% CI)
p-value
Year of survey
2007 1 1
2012 1.00 (0.77–1.30)
0.99
0.89 (0.67–1.18)
0.41
Age group, years
40–49 0.08 (0.05–0.14) 0.06 (0.03–0.12)
50–59 1 1
60–69 0.95 (0.71–1.27) 0.82 (0.60–1.12)
70–79 0.21 (0.13–0.33)
<0.001
0.18 (0.11–0.31)
<0.001
BMI group
Underweight 1.54 (0.77–3.09) 1.96 (0.99–3.88)
Normal 1 1
Overweight 1.34 (0.99–1.81) 1.19 (0.87–1.63)
Obese 1.47 (0.94–2.30)
0.11
1.34 (0.85–2.12)
0.30
Cantonal mammography screening pro-
gramme*
None 1 1
Recently introduced 8.73 (4.89–15.58) 9.32 (5.09–17.06)
Long-standing 21.16 (12.53–35.73)
<0.001
24.13 (13.39–43.50)
<0.001
Setting
Urban 1 1
Rural 1.23 (0.93–1.62)
0.14
1.10 (0.82–1.46)
0.53
Citizenship
Swiss 1 1
Non-Swiss 1.03 (0.62–1.71)
0.91
1.07 (0.61–1.85)
0.82
Education level
Primary 1 1
Profession 0.67 (0.46–0.97) 0.93 (0.63–1.36)
Secondary 1.28 (0.73–2.22) 1.70 (0.97–2.97)
Tertiary 0.70 (0.45–1.08)
0.016
0.84 (0.53–1.34)
0.082
Smoking
Never smoked 1 1
Past smoker 1.22 (0.91–1.64) 0.93 (0.68–1.25)
Current smoker 0.85 (0.61–1.19)
0.13
0.71 (0.50–1.02)
0.18
Self-reported health status
Very good 1 1
Good 1.14 (0.84–1.56) 1.21 (0.87–1.68)
Moderate 1.75 (1.14–2.70) 1.47 (0.94–2.30)
Bad 1.35 (0.68–2.67) 0.91 (0.43–1.90)
Very bad 2.00 (0.64–6.21)
0.10
0.99 (0.25–3.92)
0.44
Haemoccult screening†
Yes 1.00 (0.75–1.33) 1.16 (0.84–1.62)
No 1
0.99
1
0.37
Endoscopy screening†
Yes 1.28 (0.98–1.69) 1.02 (0.75–1.39)
No 1
0.075
1
0.88
Hospital stay insurance
Basic 1 1
Semiprivate 0.74 (0.54–1.00) 0.68 (0.48–0.95)
Private 1.05 (0.70–1.56) 0.95 (0.61–1.47)
Other 0.47 (0.17–1.30)
0.12
0.66 (0.22–2.01)
0.14
BMI = body mass index; CI = confidence interval; OR = odds ratio Model adjusted for all variables included in the table. * Recently introduced programmes: Neuchatel, Jura,
Thurgau, St. Gallen, Graubünden; long-standing programmes: Fribourg, Waadt, Wallis, Genf † Screening for colon cancer ever in life
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Table S3: Associations of opportunistic mammography (screening without clinical symptoms) with sociodemographic characteristics and health-related factors compared with all
other women aged 40–79 years in Switzerland, 2007 and 2012.
Women reporting opportunistic mammography compared with all othersCharacteristic
Unadjusted OR
(95% CI)
p-value Adjusted OR
(95% CI)
p-value
Year of survey
2007 1 1
2012 0.48 (0.41–0.57)
<0.001
0.48 (0.40–0.58)
<0.001
Age group, years
40–49 0.49 (0.38–0.63) 0.55 (0.43–0.71)
50–59 1 1
60–69 1.16 (0.95–1.43) 1.10 (0.89–1.36)
70–79 0.58 (0.45–0.76)
<0.001
0.53 (0.40–0.71)
<0.001
BMI group
Underweight 1.07 (0.71–1.61) 1.04 (0.67–1.60)
Normal 1 1
Overweight 1.05 (0.86–1.28) 1.10 (0.89–1.36)
Obese 0.85 (0.65–1.12)
0.55
0.93 (0.69–1.27)
0.53
Cantonal mammography screening programme*
None 1 1
Recently introduced 0.85 (0.65–1.10) 0.94 (0.72–1.24)
Long-standing 1.28 (1.05–1.56)
0.008
1.28 (1.04–1.58)
0.042
Setting
Urban 1 1
Rural 0.72 (0.59–0.87)
0.001
0.81 (0.67–1.0)
0.045
Citizenship
Swiss 1 1
Non-Swiss 1.05 (0.78–1.42)
0.73
1.10 (0.79–1.54)
0.58
Education level
Primary 1 1
Profession 1.10 (0.86–1.39) 1.0 (0.77–1.31)
Secondary 1.01 (0.67–1.53) 0.82 (0.53–1.26)
Tertiary 1.01 (0.76–1.35)
0.81
0.90 (0.65–1.25)
0.65
Smoking
Never smoked 1 1
Past smoker 1.13 (0.92–1.38) 1.0 (0.82–1.23)
Current smoker 0.97 (0.78–1.20)
0.40
1.0 (0.79–1.26)
0.99
Self-reported health status
Very good 1 1
Good 1.06 (0.87–1.29) 0.84 (0.68–1.04)
Moderate 0.90 (0.68–1.17) 0.78 (0.57–1.07)
Bad 1.35 (0.83–2.20) 1.13 (0.68–1.90)
Very bad 1.56 (0.40–6.07)
0.46
1.27 (0.36–4.54)
0.30
Haemoccult screening†
Yes 1.37 (1.14–1.65) 1.14 (0.93–1.39)
No 1
0.001
1
0.22
Endoscopy screening†
Yes 1.39 (1.17–1.66) 1.39 (1.15–1.68)
No 1
<0.001
1
0.001
Hospital stay insurance
Basic 1 1
Semiprivate 1.59 (1.31–1.93) 1.43 (1.17–1.74)
Private 1.81 (1.43–2.29) 1.54 (1.21–1.97)
Other 0.90 (0.42–1.91)
<0.001
1.03 (0.49–2.18)
<0.001
BMI = body mass index; CI = confidence interval; OR = odds ratio Model adjusted for all variables included in the table. * Recently introduced programmes: Neuchatel, Jura,
Thurgau, St. Gallen, Graubünden; long-standing programmes: Fribourg, Waadt, Wallis, Genf † Screening for colon cancer ever in life
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Figure S1: Geographical distribution of the cantons in Switzerland.
Figure S2: Geographical distribution of self-reported mammography in the last 12 months in women aged 40–79 years in Switzerland, 2007
and 2012. A. Programmatic mammography within a systematic cancer screening programme). B. Opportunistic mammography (screening
mammography without clinical symptoms).
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